DiaMedica Therapeutics Inc. (NASDAQ:DMAC)
| Market Cap | 430.53M+14.8% |
| Revenue (ttm) | 0 |
| Net Income | -37.54M-26.9% |
| EPS | -0.72-4.3% |
| Shares Out | 53.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 220,732 |
| Open | 8.01 |
| Previous Close | 8.13 |
| Day's Range | 7.95 - 8.41 |
| 52-Week Range | 5.25 - 10.42 |
| Beta | 0.91 |
| Analysts | Buy |
| Price Target | 8.33(+4.26%) |
| Earnings Date | Nov 11, 2026 |
Insiders here have filed 1 Form 4 in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
About DMAC
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DMAC stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in DMAC holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DMAC's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DMAC Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New DMAC patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DMAC from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in DMAC
| ETF | Est. Holding Size |
|---|---|
| IWMiShares Russell 2000 ETF | $7.69M |
| IWOiShares Russell 2000 Growth ETF | $2.83M |
| VXFVanguard Extended Market ETF | $2.29M |
| VTWOVanguard Russell 2000 ETF | $1.33M |
| IWCiShares Micro-Cap ETF | $933.15K |
| VTWGVanguard Russell 2000 Growth ETF | $257.27K |
Estimated from each fund’s disclosed top holdings × AUM
DMAC Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DMAC’s recent data — informational, not investment advice